Limited coverage drugs – risperidone microspheres

Last updated on September 26, 2024

Generic name

risperidone microspheres

Strength 

12.5 mg/2 mL, 25 mg/2 mL, 37.5 mg/2 mL, 50 mg/2 mL                                                                  

Form

injection

Special Authority criteria

Approval period

For managing the manifestations of schizophrenia or related psychotic disorders (not dementia-related) in:

  1. patients who have tried oral risperidone, aripiprazole, or paliperidone PLUS at least one other antipsychotic agent AND continue to be inadequately controlled at maximally tolerated doses

OR

  1. patients who are currently receiving a conventional depot antipsychotic PLUS are experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia

OR

  1. patients with a history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizations

Indefinite

Practitioner exemptions

  • None

Special notes

  • Criteria applicable to all plans including Plan G
  • Coverage is not available for this formulation under Plan P

Special Authority requests